Fuzheng Huayu Capsule Attenuates Hepatic Fibrosis by Inhibiting Activation of Hepatic Stellate Cells.
Journal
Evidence-based complementary and alternative medicine : eCAM
ISSN: 1741-427X
Titre abrégé: Evid Based Complement Alternat Med
Pays: United States
ID NLM: 101215021
Informations de publication
Date de publication:
2020
2020
Historique:
received:
09
08
2019
accepted:
02
03
2020
entrez:
27
5
2020
pubmed:
27
5
2020
medline:
27
5
2020
Statut:
epublish
Résumé
To investigate the mechanisms of Fuzheng Huayu (FZHY) Capsule in the treatment of hepatitis B (HBV)- associated fibrosis, HBV patients were divided into two groups, 50 cases were in the nucleotide analogues (NAs) group, while additional 50 cases were in the NAs + FZHY group. We assessed the curative effects of antifibrosis through liver function, FibroScan test, and liver biopsy and detected the ratio of lymphocyte subsets by flow cytometry. Peripheral blood lymphocyte and CD8 It is evident that FZHY treatment significantly increased the percentage of NK cells, the rate of death, and apoptosis of LX-2 cells and decreased the FibroScan liver stiffness measurement value. The expressions of FZHY Capsule improved the disordered cellular immunity and postponed liver fibrosis possibly through inhibiting the interaction between lymphocyte and hepatic stellate cells.
Identifiants
pubmed: 32454856
doi: 10.1155/2020/3468791
pmc: PMC7243025
doi:
Types de publication
Journal Article
Langues
eng
Pagination
3468791Informations de copyright
Copyright © 2020 Mei Wu et al.
Déclaration de conflit d'intérêts
The authors declare that they have no conflicts of interest.
Références
Inflammation. 2009 Aug;32(4):218-32
pubmed: 19434485
Lab Invest. 2012 Jul;92(7):967-77
pubmed: 22449797
Evid Based Complement Alternat Med. 2013;2013:534960
pubmed: 23762144
Hepatology. 2017 Mar;65(3):983-998
pubmed: 28039913
J Hepatol. 2010 Jun;52(6):949-50
pubmed: 20395006
Clin Sci (Lond). 2007 Mar;112(5):265-80
pubmed: 17261089
J Immunol. 2013 Aug 15;191(4):1835-44
pubmed: 23842754
J Hepatol. 2015 Jan;62(1):156-64
pubmed: 25111176
Hepatology. 2008 Sep;48(3):963-77
pubmed: 18726940
Liver Int. 2015 Oct;35(10):2246-55
pubmed: 25682719
Eur J Gastroenterol Hepatol. 2015 Sep;27(9):1074-9
pubmed: 26011235
Cell Mol Immunol. 2012 Jul;9(4):296-301
pubmed: 22157623
Am J Chin Med. 2009;37(2):361-72
pubmed: 19507278
Dig Dis. 2015;33 Suppl 2:115-7
pubmed: 26642068
Dig Dis Sci. 2015 Sep;60(9):2825-31
pubmed: 25972148
Chin J Integr Med. 2012 May;18(5):398-400
pubmed: 22438173
J Gastroenterol Hepatol. 2013 Aug;28 Suppl 1:99-104
pubmed: 23855303
J Integr Med. 2014 Sep;12(5):401-8
pubmed: 25292339
Semin Liver Dis. 2010 Aug;30(3):226-31
pubmed: 20665375
Front Immunol. 2012 Apr 10;3:71
pubmed: 22566952
World J Gastroenterol. 2005 May 21;11(19):2892-9
pubmed: 15902724
Exp Ther Med. 2014 Oct;8(4):1123-1126
pubmed: 25187808
J Hepatol. 1991 Nov;13(3):372-4
pubmed: 1808228
Methods Find Exp Clin Pharmacol. 2008 Jul-Aug;30(6):421-9
pubmed: 18850043
Gut. 2011 Jan;60(1):90-8
pubmed: 20660699
J Hepatol. 2013 Sep;59(3):427-33
pubmed: 23665286
J Clin Invest. 2007 Mar;117(3):539-48
pubmed: 17332881